US EditionInhaleRX sets up Phase 1 trial for panic disorder inhaler
Summary by themarketonline.com.au
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
InhaleRX sets up Phase 1 trial for panic disorder inhaler
InhaleRX (ASX:IRX) has taken a crucial step to initiate research into IRX-616a – the drug candidate it’s developing to treat panic disorder – by executing a Study Order with iNGENū CRO Pty Ltd for the latter to oversee a Phase One clinical trial in Adelaide. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. This follows the Oz biotech company …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
